Who is sponsoring NCT05662358?

NCT05662358 is sponsored by Shenzhen People's Hospital.

What condition does NCT05662358 study?

NCT05662358 studies Denosumab Allergy.

What drugs are being tested in NCT05662358?

Interventions: Denosumab, Alendronate, Placebo.

What is the status of NCT05662358?

NCT05662358 is currently UNKNOWN.

Last reviewed 2023-02-21 · How we verify

Denosumab vs Alendronate After Vertebroplasty

NCT05662358 NA UNKNOWN

Osteoporotic vertebral compression fracture (OVCF) patients had a proportion of secondary fractures after percutaneous vertebroplasty (PVP). Denosumab and alendronate is both effective to prevent bone loss for OVCF postmenopausal women. However, trial evidence comparing effect of denosumab vs zoledronate after PVP was unknown. The study aims to assess the efficiency of denosumab vs alendronate for OVCF patients bone mineral density (BMD), bone turnover markers (BTMs), secondary fracture and adverse events after PVP

Details

Lead sponsor	Shenzhen People's Hospital
Phase	NA
Status	UNKNOWN
Enrolment	90
Start date	Sun Jan 03 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Oct 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Denosumab Allergy

Interventions

Denosumab
Alendronate
Placebo

Countries

China